Cargando…

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer

Breast Cancer (BC) is a highly prevalent disease. A woman living in the United States has a 12.3% lifetime risk of being diagnosed with breast cancer [1]. It is the most common female cancer and the second most common cause of cancer death in women [2]. Of note, amplification or overexpression of Hu...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Melo Gagliato, Debora, Leonardo Fontes Jardim, Denis, Marchesi, Mario Sergio Pereira, Hortobagyi, Gabriel N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325455/ https://www.ncbi.nlm.nih.gov/pubmed/26824988 http://dx.doi.org/10.18632/oncotarget.7043

Ejemplares similares

Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution
por: Giugliano, Federica, et al.
Publicado: (2023)

Bevacizumab as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer: A Brazilian Center Experience
por: Jardim, Denis Leonardo Fontes, et al.
Publicado: (2012)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
por: Adam-Artigues, Anna, et al.
Publicado: (2022)

Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
por: Stanowicka-Grada, Malwina, et al.
Publicado: (2023)

Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer
por: Liu, Yunhua, et al.
Publicado: (2018)

Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
por: Atallah, N. M., et al.
Publicado: (2023)

Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors
por: Floros, Konstantinos V., et al.
Publicado: (2021)

RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer
por: Sanz-Moreno, Adrián, et al.
Publicado: (2021)

Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology
por: Jardim, Denis L., et al.
Publicado: (2018)

Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2− locally advanced breast cancer
por: Petry, V., et al.
Publicado: (2015)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
por: MacNeil, Ian A., et al.
Publicado: (2020)

Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer
por: Chen, Hai-long, et al.
Publicado: (2021)

HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment
por: Novillo, Apolonia, et al.
Publicado: (2023)

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
por: Watanabe, Satomi, et al.
Publicado: (2019)

Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer
por: Mohd Sharial, M. S. N., et al.
Publicado: (2012)

Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy
por: Crespo, James, et al.
Publicado: (2020)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
por: Gandullo‐Sánchez, Lucía, et al.
Publicado: (2020)

Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
por: Ding, Yi, et al.
Publicado: (2018)

HER-3 expression in HER-2-amplified breast carcinoma
por: Czopek, Jacek, et al.
Publicado: (2013)

Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy
por: Strasser-Weippl, Kathrin, et al.
Publicado: (2015)

HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
por: Smith, Alison E., et al.
Publicado: (2021)

Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients
por: You, Ji Young, et al.
Publicado: (2023)

Immune microenvironment dynamics of HER2 overexpressing breast cancer under dual anti-HER2 blockade
por: Batalha, Sofia, et al.
Publicado: (2023)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies
por: Vicario, Rocio, et al.
Publicado: (2015)

The anti-malarial chloroquine overcomes Primary resistance and restores sensitivity to Trastuzumab in HER2-positive breast cancer
por: Cufí, Sílvia, et al.
Publicado: (2013)

Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
por: Fiszman, Gabriel L., et al.
Publicado: (2011)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

The reversal of anti-HER2 resistance in advanced HER2-positive breast cancer using apatinib: two cases reports and literature review
por: He, Libin, et al.
Publicado: (2022)

Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
por: Baldassarre, Tomas, et al.
Publicado: (2017)

Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers
por: Khelwatty, Said A, et al.
Publicado: (2015)

Cost-effectiveness of ribociclib for premenopausal or perimenopausal women with HR+/HER2− advanced breast cancer: a Brazilian public health care system perspective
por: Rosa, Daniela Dornelles, et al.
Publicado: (2022)

Improving HER2 testing reproducibility in HER2-low breast cancer
por: Sajjadi, Elham, et al.
Publicado: (2022)

HER2/positive and HER2/low in inflammatory breast cancer recurrence
por: Movchan, Oleksii Volodimirovich, et al.
Publicado: (2022)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes
por: Watson, Spencer S., et al.
Publicado: (2018)

TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
por: Gu, Yayun, et al.
Publicado: (2022)

Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies
por: Tapia, Marta, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ipg02su1r2dno6s5ai8daa2bpm